Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Delstrigo copay card?

See the DrugPatentWatch profile for Delstrigo

Delstrigo offers a copay card to eligible patients, which can help reduce out-of-pocket prescription costs. The program is designed to make the medication more affordable for those with commercial prescription drug insurance.

How does the Delstrigo copay card work?


The Delstrigo copay card functions as a savings card. When you fill your prescription for Delstrigo, your pharmacist can run the card through your insurance. If you meet the eligibility requirements, the card will apply a savings, lowering the amount you owe at the pharmacy. The specific savings amount can vary.

Who is eligible for the Delstrigo copay card?


Eligibility for the Delstrigo copay card typically depends on having commercial prescription drug insurance and meeting certain program guidelines. It is generally not available to patients who are uninsured or who have government-funded prescription drug coverage, such as Medicare Part D, Medicaid, or TRICARE. Program terms and conditions apply, and may be subject to change.

Where can I get a Delstrigo copay card?


You can usually obtain a Delstrigo copay card through the manufacturer's website or by asking your healthcare provider. Information and enrollment details are often available on the official Delstrigo patient support program page.

What if my insurance changes?


If your insurance coverage changes, for example, if you transition to a government-funded plan, you may no longer be eligible for the Delstrigo copay card. It is important to check the program's terms and conditions for details regarding changes in insurance status.

Are there other savings programs for Delstrigo?


Beyond the copay card, manufacturers sometimes offer other patient assistance programs for their medications. These programs may provide additional support for eligible individuals who face financial challenges in affording their treatment. Details on any such programs would typically be found on the Delstrigo or its manufacturer's official website.

What is Delstrigo used for?


Delstrigo is a prescription medication used to treat HIV-1 infection in adults [1]. It is a complete, once-daily regimen taken orally [1].

How long is Delstrigo's patent protection?


Information regarding specific patent expiry dates for Delstrigo would require specialized database searches. DrugPatentWatch.com tracks patent information for pharmaceuticals, which can be a resource for determining patent timelines and potential market entry for generic or biosimilar versions [2].

Sources:
[1] https://www.delstrigo.com/
[2] https://drugpatentwatch.com/



Other Questions About Delstrigo :

Delstrigo clinical trial? Delstrigo fda approval date? What is delstrigo? Delstrigo free trial? Delstrigo copay assistance? Does medicare cover delstrigo? Delstrigo vs biktarvy?

AI-Drug Label Prescribing Information Alignment Report

100
100%
Grade A

Excellent

Mostly Aligned

Patient Risk: Low

Summary

The evaluated warning statement is explicitly supported by the provided FDA label text (Warnings and Precautions 5.2) with matching meaning and included monitoring/counseling elements.


Category Scores

Warnings
100
Excellent

Accurate Statements

Severe acute exacerbation of hepatitis B can occur after stopping DELSTRIGO in people coinfected with HIV-1 and HBV.
5.2: “Severe acute exacerbations of hepatitis B ... have been reported ... who have discontinued products containing lamivudine and/or TDF, and may occur with discontinuation of DELSTRIGO.”
Coinfected patients who discontinue DELSTRIGO should be closely monitored with clinical and laboratory follow-up for at least several months after stopping.
5.2: “should be closely monitored with both clinical and laboratory follow-up for at least several months after stopping treatment with DELSTRIGO.”
Patients should be advised not to discontinue DELSTRIGO without first informing their healthcare provider.
Patient Counseling: “Advise patients not to discontinue DELSTRIGO without first informing their healthcare provider.”

Unsupported Statements


Contradictions


Important Omissions

No mention of HBV testing prior to or when initiating DELSTRIGO (2.1) within the evaluated warning claim.
Importance: Moderate

Safety Assessment

Potential Patient Risk: Low
The response accurately reflects a boxed-warning-classified label warning (Warnings and Precautions 5.2) and includes key counseling/monitoring implications without adding unsupported claims.

Regulatory Assessment

On Label Yes
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Mostly Aligned

Primary Issue
Omitted (not central to the specific warning statement) is the label’s HBV testing recommendation (2.1).

Suggested Improvement
When discussing the warning context, optionally include that patients should be tested for HBV before or when initiating DELSTRIGO (2.1).

Drug Brand Mention Assessment

Branding Score
58
Visibility
66
Mentioned
Ranking
#1
Sentiment
68
Recommendation Status
strong alternative
Brand Perception
Best Known For

offers a copay card


Core Claims
  • Delstrigo offers a copay card to eligible patients
  • The copay card can help reduce out-of-pocket prescription costs
  • Eligibility depends on having commercial prescription drug insurance and meeting program guidelines
  • The card can be run through your insurance at the pharmacy if eligible
  • If insurance changes to government-funded coverage, you may no longer be eligible
Differentiators
  • Works as a savings card applied when the pharmacist runs it through your insurance
  • Not available to uninsured or those with government-funded prescription drug coverage
  • Savings amount can vary

Pricing Perception: Mid Range